Image analysis software developer Perspectum Diagnostics has launched a multisite study to evaluate the use of its LiverMultiScan software for identifying nonalcoholic steatohepatitis (NASH) patients who are eligible to enroll in clinical trials.
Virginia Commonwealth University, the University of Virginia, Mount Sinai, and Liver Centers of Texas are collaborating on the study, which will recruit and prospectively study 225 patients with suspected NASH over a 12-month period, Perspectum said. The company believes that quantitative characterization of liver tissue by LiverMultiScan may help sponsors accelerate and improve their success rates in clinical trial enrollment.
